Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Lee on the Role of Integrative Medicine in Oncology Care
April 10th 2025, 6:49pm
Oncology Nursing Society Congress
Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.
Subcutaneous Nivolumab Sustains Comparable Efficacy, Safety to IV Formulation in Advanced ccRCC
April 10th 2025, 5:29pm
Oncology Nursing Society Congress
Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.
Darolutamide Plus ADT Provides Clear Clinical Benefits With Acceptable Tolerability in mHSPC
April 10th 2025, 5:26pm
Oncology Nursing Society Congress
ARANOTE data underscore that combining darolutamide with ADT benefits patients with mHSPC irrespective of whether they also receive docetaxel.
Tailored Interventions Are Needed to Reduce Barriers to Breast Cancer Screening in Jordan
April 10th 2025, 5:20pm
Oncology Nursing Society Congress
A study identified individual and non-individual factors as barriers to breast cancer screening for women in Jordan.
Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis
April 10th 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how real-world analyses of chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory multiple myeloma (R/R MM), as presented in abstract #2408 by Amoozgar et al at ASH 2024, provide insights into the comparative efficacy and safety of ciltacabtagene autoleucel and idecabtagene vicleucel, highlighting differences between real-world outcomes and clinical trial results.
Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024
April 10th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how key data from ASH 2024 impact current approaches to treating hematologic malignancies, with a focus on multiple myeloma, lymphoma, and leukemia.
Intravenous Sirolimus Shows Tolerability, Early Efficacy in Malignant PEComa
April 9th 2025, 10:57pm
ESMO Sarcoma and Rare Cancers Congress
Phase 1b data support further exploration of intravenous sirolimus in patients with malignant PEComa.
Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC
April 9th 2025, 6:00pm
Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.
Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC
April 9th 2025, 12:00pm
Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.
Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC
April 8th 2025, 8:00pm
Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.
Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC
April 7th 2025, 8:40pm
Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.
FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL
April 4th 2025, 6:00pm
A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.
Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis
April 3rd 2025, 10:05pm
Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.
Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis
April 3rd 2025, 9:43pm
Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies
April 3rd 2025, 9:02pm
Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.
Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
April 2nd 2025, 10:40pm
Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.
Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease
April 2nd 2025, 9:15pm
Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.
Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL
April 2nd 2025, 8:51pm
Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.
Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD
April 2nd 2025, 8:45pm
A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.
ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL
April 2nd 2025, 8:23pm
Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.